Rapid in vivo testing of drug response in multiple myeloma made possible by xenograft to turkey embryos

BACKGROUND: The best current xenograft model of multiple myeloma (MM) in immune-deficient non-obese diabetic/severe-combined immunodeficient mice is costly, animal maintenance is complex and several weeks are required to establish engraftment and study drug efficacy. More practical in vivo models ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Farnoushi, Y, Cipok, M, Kay, S, Jan, H, Ohana, A, Naparstek, E, Goldstein, R S, Deutsch, V R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242603/
https://www.ncbi.nlm.nih.gov/pubmed/22045188
http://dx.doi.org/10.1038/bjc.2011.445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242603/
https://www.ncbi.nlm.nih.gov/pubmed/22045188
http://dx.doi.org/10.1038/bjc.2011.445

Ejemplares similares